Journal of Cancer Epidemiology / 2013 / Article / Tab 4

Research Article

Cancer Incidence and Mortality in a Cohort of US Blood Donors: A 20-Year Study

Table 4

Adjusted Cox proportional regression models for all-cause mortality, comparing donors and nondonors with cancer, by cancer site, Blood Centers of the Pacific and California Cancer Registry, 1991–2009 ( = 24,927).

DonorsNondonorsAdjusted HR* -value
(%)Mortality (%) (%)Mortality (%)

All cancer sites**4,805(100)27.120,122(100)45.00.70<0.001
 Followup < 5 years2,519(52.4)42.011,319(56.3)59.10.75<0.001
 Followup 5 years2,286(47.6)10.68,803(43.7)27.00.65<0.001
By cancer site
 Oral cavity and pharynx80(1.7)40.0322(1.6)52.80.660.05
 Digestive559(11.6)48.12,395(11.9)68.90.70<0.001
 Respiratory348(7.2)83.31,653(8.2)86.60.930.25
 Skin487(10.1)7.61,628(8.1)18.00.57<0.01
 Breast914(19.0)10.53,451(17.2)27.20.51<0.001
 Female genital405(8.4)16.81,735(8.6)32.10.68<0.01
 Male genital1,025(21.3)14.25,010(24.9)39.30.57<0.001
 Urinary241(5.0)30.71,078(5.4)53.40.70<0.01
 Brain and nervous117(2.4)47.9451(2.2)56.30.680.01
 Endocrine114(2.4)3.5409(2.0)11.50.25<0.01
 Lymphoma219(4.6)28.3822(4.6)47.70.55<0.001
 Myeloma50(1.0)66.0176(1.0)68.21.001.00
 Leukemia104(2.2)51.0385(1.9)65.20.700.03
 Other142(3.0)57.0607(3.0)68.40.980.89

Adjusted models include age at diagnosis, sex, race, tumor metastasis, tumor stage and grade, and SES.
**Cox models are stratified by cancer site; that is, baseline hazard is adjusted by site.
Other includes mesothelioma, Kaposi sarcoma, eye and orbit, bone, soft tissue, and miscellaneous (SEER site recode ICD-O-3 definition).